Online konsultationer skiljer sig så?

bjutatorp: Hur man än vrider och vänder på det så spelar de i samma liga, det tror jag vi kan enas om :D

Ted: Först vill jag klargöra att minoxidil, för de allra flesta, definitivt “hjälper” mot genetiskt håravfall.

Mig veterligen finns det ett flertal studier (te.x.http://www.ncbi.nlm.nih.gov/pubmed/2826267) som tidigt påvisat, med varierad tillförlitlighet, att minoxidil molekylens mörkare sida, i synnerhet beträffande kollagen. Själv tycker jag inte att de studier jag tagit del av har varit tillräckligt konkreta för att utom rimliga tvivel avstå ifrån användande av minoxidil i topikal form…men inkluderar man den mängd bieffektsrapporter jag på olika sätt fått till mig av en mängd olika användare genom åren, känns slutsatsen mer självklar – minoxidil kan orsaka ansiktsrynkor.

Om detta förekom i någon större utsträckning så borde väl nätet krylla av före och efterbilder?

Vad innebär “större utsträckning?” Vad innebär “försumbar” ?

Jag har ingen siffra på hur länge den genomsnittslige minoxanvändaren orkar hålla på med produkten innan avbrott sker, men hos majoriteten av användarna så har jag svårt att tänka mig att omfattande rynkor pga minoxidil uppstår…men att antalet som drabbas skulle vara försumbar..är jag tveksam till…men ej heller vanligt förekommande..

Andra, mindre allvarliga hudbieffekter är definitivt frekventare förekommande vid minoxidilanvändning och har rapporterats busslassvis genom alla år.

Minox studier för den som vill förstå molekylen bättre wrote: Limas CJ, Freis ED. Minoxidil in severe hypertension with renal failure. Effect of its addition to conventional antihypertensive drugs. Am J Cardiol 1973; 31: 355-61.

Mehta PK, Mamdani B, Shansky RM et al. Severe hypertension. Treatment with minoxidil. JAMA 1975; 233: 249-52.

Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med 1980; 303: 1480-1.

Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 1990; 17: 276-81.

Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 1987; 16: 657-68.

Courtois M, Loussouarn G, Hourseau C et al. Ageing and hair cycles. Br J Dermatol 1995; 132: 86-93.

Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28: 755-63.

Rushton DH, Ramsay ID, James KC et al. Biochemical and trichological characterization of diffuse alopecia in women. Br J Dermatol 1990; 123: 187-97.

Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol 1996; 35: 899-906.

Abell E. Histologic response to topically applied minoxidil in male-pattern alopecia. Clin Dermatol 1988; 6: 191-4.

Headington JT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res Clin Exp 1984; 36: 1098-106.

Johnson GA, Barsuhn KJ, McCall JM. Sulfation of minoxidil by liver sulfotransferase. Biochem Pharmacol 1982; 31: 2949-54.

Meisheri KD, Johnson GA, Puddington L. Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem Pharmacol 1993; 45: 271-9.

Falany CN, Kerl EA. Sulfation of minoxidil by human liver phenol sulfotransferase. Biochem Pharmacol 1990; 40: 1027-32.

Johnson GA, Baker CA. Sulfation of minoxidil by human platelet sulfotransferase. Clin Chim Acta 1987; 169: 217-27.

Johnson GA, Baker CA, Knight KA. Minoxidil sulfotransferase, a marker of human keratinocyte differentiation. J Invest Dermatol 1992; 98: 730-3.

Buhl AE, Waldon DJ, Baker CA et al. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol 1990; 95: 553-7.

Dooley TP, Walker CJ, Hirshey SJ et al. Localization of minoxidil sulfotransferase in rat liver and the outer root sheath of anagen pelage and vibrissa follicles. J Invest Dermatol 1991; 96: 65-70.

Hamamoto T, Mori Y. Sulfation of minoxidil in keratinocytes and hair follicles. Res Commun Chem Pathol Pharmacol 1989; 66: 33-44.

Baker CA, Uno H, Johnson GA. Minoxidil sulfation in the hair follicle. Skin Pharmacol 1994; 7: 335-9.

Dooley TP. Molecular biology of the human cytosolic sulferotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Exp Dermatol 1999; 8: 328-9.

Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact 1998; 109: 53-67.

Buhl AE, Baker CA, Dietz AJ et al. Minoxidil sulfotransferase activity influences the efficacy of Rogaine topical solution (TS): enzyme studies using scalp and platelets. J Invest Dermatol 1994; 102: 534.

Meisheri KD, Cipkus LA, Taylor CJ. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther 1988; 245: 751-60.

Winquist RJ, Heaney LA, Wallace AA et al. Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J Pharmacol Exp Ther 1989; 248: 149-56.

Schwanstecher M, Sieverding C, Dorschner H et al. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 1998; 17: 5529-35.

Yost CS. Potassium channels. Basic aspects, functional roles and medical significance. Anesthesiol 1999; 90: 1186-203.

Yokoshiki H, Sunagawa M, Seki T et al. ATP-sensitive K+ channels in pancreatic, cardiac and vascular smooth muscle cells. Am J Physiol 1998; 274: C25-C37.

Xu D, Wang L, Dai W et al. A requirement for K+-channel activity in growth factor-mediated extracellular signal-regulated kinase activation in human myeloblastic leukemia ML-1 cells. Blood 1999; 94: 139-45.

Malhi H, Irani AN, Rajvanshi P et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem 2000; 275: 26050-7.

Koblenzer PJ, Baker L. Hypertrichosis lanuginosa associated with diazoxide therapy in prepubertal children: a clinicopathologic study. Ann N Y Acad Sci 1968; 150: 373-82.

Burton JL, Schutt WH, Caldwell IW. Hypertrichosis due to diazoxide. Br J Dermatol 1975; 93: 707-11.

Goldberg MR. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 1988; 12 (Suppl. 2): S41-7.

Buhl AE, Conrad SJ, Waldon DJ et al. Potassium channel conductance as a control mechanism in hair follicles. J Invest Dermatol 1993; 101: 148S-52S.

Buhl AE, Waldon DJ, Kawabe TT et al. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol 1989; 92: 315-20.

Buhl AE, Waldon DJ, Conrad SJ et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992; 98: 315-19.

Harmon CS, Lutz D, Ducote J. Potassium channel openers stimulate DNA synthesis in mouse epidermal keratinocyte and whole hair follicle cultures. Skin Pharmacol 1993; 6: 170-8.

Imai R, Jindo T, Miura Y et al. Organ culture of human hair follicles in serum-free medium. Arch Dermatol Res 1993; 284: 466-71.

Sanders DA, Fiddes I, Thompson DM et al. In the absence of streptomycin, minoxidil potentiates the mitogenic effects of fetal calf serum, insulin-like growth factor 1, and platelet-derived growth factor on NIH 3T3 fibroblasts in a K+ channel-dependent fashion. J Invest Dermatol 1996; 107: 229-34.

Nakaya Y, Hamaoka H, Kato S et al. Effect of minoxidil sulfate and pinacidil on single potassium channel current in cultured human outer root sheath cells and dermal papilla cells. J Dermatol Sci 1994; 7 (Suppl.): S104-S8.

Li M, Marubayashi A, Nakaya Y et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol 2001; 117: 1594-600.

Buhl AE. Minoxidil’s action in hair follicles. J Invest Dermatol 1991; 96: 73S-4S.

Buhl AE, Kawabe TT, MacCallum DK et al. Interaction of minoxidil with pigment in cells of the hair follicle: an example of binding without apparent biological effects. Skin Pharmacol 1992; 5: 114-23.

Boyera N, Galey I, Bernard BA. Biphasic effects of minoxidil on the proliferation and differentiation of normal human keratinocytes. Skin Pharmacol 1997; 10: 206-20.

Kurata S, Uno H, Allen-Hoffmann BL. Effects of hypertrichotic agents on follicular and nonfollicular cells in vitro. Skin Pharmacol 1996; 9: 3-8.

O’Keefe E, Payne RE Jr. Minoxidil: inhibition of proliferation of keratinocytes in vitro. J Invest Dermatol 1991; 97: 534-6.

Baden HP, Kubilus J. Effect of minoxidil on cultured keratinocytes. J Invest Dermatol 1983; 81: 558-60.

Murad S, Pinnell SR. Suppression of fibroblast proliferation and lysyl hydroxylase activity by minoxidil. J Biol Chem 1987; 262: 11973-8.

Murad S, Walker LC, Tajima S et al. Minimum structural requirements for minoxidil inhibition of lysyl hydroxylase in cultured fibroblasts. Arch Biochem Biophys 1994; 308: 42-7.

Lachgar S, Charveron M, Bouhaddioui N et al. Inhibitory effects of bFGF, VEGF and minoxidil on collagen synthesis by cultured hair dermal papilla cells. Arch Dermatol Res 1996; 288: 469-73.

Michelet JF, Commo S, Billoni N et al. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol 1997; 108: 205-9.

Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol 1988; 37: 867-74.

Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002; 68-9: 535-56.

Gilmour RS, Mitchell MD. Nuclear lipid signaling: novel role of eicosanoids. Exp Biol Med (Maywood) 2001; 226: 1-4.

Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-7.

Uno H, Zimbric ML, Albert DM et al. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol 2002; 82: 7-12.

Nuck BA, Fogelson SL, Lucky AW. Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Arch Dermatol 1987; 123: 59-61.

Sato T, Tadokoro T, Sonoda T et al. Minoxidil increases 17 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity of cultured human dermal papilla cells from balding scalp. J Dermatol Sci 1999; 19: 123-5.

Wester RC, Maibach HI, Guy RH et al. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 1984; 82: 515-17.

Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol 1987; 117: 668-9.

Sakita S, Kagoura M, Toyoda M et al. The induction by topical minoxidil of increased fenestration in the perifollicular capillary wall. Br J Dermatol 1999; 140: 294-6.

Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.

Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-17.

Lachgar S, Charveron M, Gall Y et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-11.

Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41: 717-21.

Olsen EA, Dunlap FE, Funicella T et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377-85.

Helt sant! Duktiga båda två. Det som väger över på Demirsoy är att han endast tar sig an en patient per dag och gör det mesta av proceduren själv, medan dr Hakan låter teknikerna sköta flera moment..

whyatt wrote: bjutatorp: Hur man än vrider och vänder på det så spelar de i samma liga, det tror jag vi kan enas om :D

Ted: Först vill jag klargöra att minoxidil, för de allra flesta, definitivt “hjälper” mot genetiskt håravfall.

Mig veterligen finns det ett flertal studier (te.x.http://www.ncbi.nlm.nih.gov/pubmed/2826267) som tidigt påvisat, med varierad tillförlitlighet, att minoxidil molekylens mörkare sida, i synnerhet beträffande kollagen. Själv tycker jag inte att de studier jag tagit del av har varit tillräckligt konkreta för att utom rimliga tvivel avstå ifrån användande av minoxidil i topikal form…men inkluderar man den mängd bieffektsrapporter jag på olika sätt fått till mig av en mängd olika användare genom åren, känns slutsatsen mer självklar – minoxidil kan orsaka ansiktsrynkor.

Om detta förekom i någon större utsträckning så borde väl nätet krylla av före och efterbilder?

Vad innebär “större utsträckning?” Vad innebär “försumbar” ?

Jag har ingen siffra på hur länge den genomsnittslige minoxanvändaren orkar hålla på med produkten innan avbrott sker, men hos majoriteten av användarna så har jag svårt att tänka mig att omfattande rynkor pga minoxidil uppstår…men att antalet som drabbas skulle vara försumbar..är jag tveksam till…men ej heller vanligt förekommande..

Andra, mindre allvarliga hudbieffekter är definitivt frekventare förekommande vid minoxidilanvändning och har rapporterats busslassvis genom alla år.

Limas CJ, Freis ED. Minoxidil in severe hypertension with renal failure. Effect of its addition to conventional antihypertensive drugs. Am J Cardiol 1973; 31: 355-61.

Mehta PK, Mamdani B, Shansky RM et al. Severe hypertension. Treatment with minoxidil. JAMA 1975; 233: 249-52.

Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med 1980; 303: 1480-1.

Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 1990; 17: 276-81.

Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 1987; 16: 657-68.

Courtois M, Loussouarn G, Hourseau C et al. Ageing and hair cycles. Br J Dermatol 1995; 132: 86-93.

Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28: 755-63.

Rushton DH, Ramsay ID, James KC et al. Biochemical and trichological characterization of diffuse alopecia in women. Br J Dermatol 1990; 123: 187-97.

Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol 1996; 35: 899-906.

Abell E. Histologic response to topically applied minoxidil in male-pattern alopecia. Clin Dermatol 1988; 6: 191-4.

Headington JT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res Clin Exp 1984; 36: 1098-106.

Johnson GA, Barsuhn KJ, McCall JM. Sulfation of minoxidil by liver sulfotransferase. Biochem Pharmacol 1982; 31: 2949-54.

Meisheri KD, Johnson GA, Puddington L. Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem Pharmacol 1993; 45: 271-9.

Falany CN, Kerl EA. Sulfation of minoxidil by human liver phenol sulfotransferase. Biochem Pharmacol 1990; 40: 1027-32.

Johnson GA, Baker CA. Sulfation of minoxidil by human platelet sulfotransferase. Clin Chim Acta 1987; 169: 217-27.

Johnson GA, Baker CA, Knight KA. Minoxidil sulfotransferase, a marker of human keratinocyte differentiation. J Invest Dermatol 1992; 98: 730-3.

Buhl AE, Waldon DJ, Baker CA et al. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol 1990; 95: 553-7.

Dooley TP, Walker CJ, Hirshey SJ et al. Localization of minoxidil sulfotransferase in rat liver and the outer root sheath of anagen pelage and vibrissa follicles. J Invest Dermatol 1991; 96: 65-70.

Hamamoto T, Mori Y. Sulfation of minoxidil in keratinocytes and hair follicles. Res Commun Chem Pathol Pharmacol 1989; 66: 33-44.

Baker CA, Uno H, Johnson GA. Minoxidil sulfation in the hair follicle. Skin Pharmacol 1994; 7: 335-9.

Dooley TP. Molecular biology of the human cytosolic sulferotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Exp Dermatol 1999; 8: 328-9.

Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact 1998; 109: 53-67.

Buhl AE, Baker CA, Dietz AJ et al. Minoxidil sulfotransferase activity influences the efficacy of Rogaine topical solution (TS): enzyme studies using scalp and platelets. J Invest Dermatol 1994; 102: 534.

Meisheri KD, Cipkus LA, Taylor CJ. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther 1988; 245: 751-60.

Winquist RJ, Heaney LA, Wallace AA et al. Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J Pharmacol Exp Ther 1989; 248: 149-56.

Schwanstecher M, Sieverding C, Dorschner H et al. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 1998; 17: 5529-35.

Yost CS. Potassium channels. Basic aspects, functional roles and medical significance. Anesthesiol 1999; 90: 1186-203.

Yokoshiki H, Sunagawa M, Seki T et al. ATP-sensitive K+ channels in pancreatic, cardiac and vascular smooth muscle cells. Am J Physiol 1998; 274: C25-C37.

Xu D, Wang L, Dai W et al. A requirement for K+-channel activity in growth factor-mediated extracellular signal-regulated kinase activation in human myeloblastic leukemia ML-1 cells. Blood 1999; 94: 139-45.

Malhi H, Irani AN, Rajvanshi P et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem 2000; 275: 26050-7.

Koblenzer PJ, Baker L. Hypertrichosis lanuginosa associated with diazoxide therapy in prepubertal children: a clinicopathologic study. Ann N Y Acad Sci 1968; 150: 373-82.

Burton JL, Schutt WH, Caldwell IW. Hypertrichosis due to diazoxide. Br J Dermatol 1975; 93: 707-11.

Goldberg MR. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 1988; 12 (Suppl. 2): S41-7.

Buhl AE, Conrad SJ, Waldon DJ et al. Potassium channel conductance as a control mechanism in hair follicles. J Invest Dermatol 1993; 101: 148S-52S.

Buhl AE, Waldon DJ, Kawabe TT et al. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol 1989; 92: 315-20.

Buhl AE, Waldon DJ, Conrad SJ et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992; 98: 315-19.

Harmon CS, Lutz D, Ducote J. Potassium channel openers stimulate DNA synthesis in mouse epidermal keratinocyte and whole hair follicle cultures. Skin Pharmacol 1993; 6: 170-8.

Imai R, Jindo T, Miura Y et al. Organ culture of human hair follicles in serum-free medium. Arch Dermatol Res 1993; 284: 466-71.

Sanders DA, Fiddes I, Thompson DM et al. In the absence of streptomycin, minoxidil potentiates the mitogenic effects of fetal calf serum, insulin-like growth factor 1, and platelet-derived growth factor on NIH 3T3 fibroblasts in a K+ channel-dependent fashion. J Invest Dermatol 1996; 107: 229-34.

Nakaya Y, Hamaoka H, Kato S et al. Effect of minoxidil sulfate and pinacidil on single potassium channel current in cultured human outer root sheath cells and dermal papilla cells. J Dermatol Sci 1994; 7 (Suppl.): S104-S8.

Li M, Marubayashi A, Nakaya Y et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol 2001; 117: 1594-600.

Buhl AE. Minoxidil’s action in hair follicles. J Invest Dermatol 1991; 96: 73S-4S.

Buhl AE, Kawabe TT, MacCallum DK et al. Interaction of minoxidil with pigment in cells of the hair follicle: an example of binding without apparent biological effects. Skin Pharmacol 1992; 5: 114-23.

Boyera N, Galey I, Bernard BA. Biphasic effects of minoxidil on the proliferation and differentiation of normal human keratinocytes. Skin Pharmacol 1997; 10: 206-20.

Kurata S, Uno H, Allen-Hoffmann BL. Effects of hypertrichotic agents on follicular and nonfollicular cells in vitro. Skin Pharmacol 1996; 9: 3-8.

O’Keefe E, Payne RE Jr. Minoxidil: inhibition of proliferation of keratinocytes in vitro. J Invest Dermatol 1991; 97: 534-6.

Baden HP, Kubilus J. Effect of minoxidil on cultured keratinocytes. J Invest Dermatol 1983; 81: 558-60.

Murad S, Pinnell SR. Suppression of fibroblast proliferation and lysyl hydroxylase activity by minoxidil. J Biol Chem 1987; 262: 11973-8.

Murad S, Walker LC, Tajima S et al. Minimum structural requirements for minoxidil inhibition of lysyl hydroxylase in cultured fibroblasts. Arch Biochem Biophys 1994; 308: 42-7.

Lachgar S, Charveron M, Bouhaddioui N et al. Inhibitory effects of bFGF, VEGF and minoxidil on collagen synthesis by cultured hair dermal papilla cells. Arch Dermatol Res 1996; 288: 469-73.

Michelet JF, Commo S, Billoni N et al. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol 1997; 108: 205-9.

Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol 1988; 37: 867-74.

Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002; 68-9: 535-56.

Gilmour RS, Mitchell MD. Nuclear lipid signaling: novel role of eicosanoids. Exp Biol Med (Maywood) 2001; 226: 1-4.

Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-7.

Uno H, Zimbric ML, Albert DM et al. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol 2002; 82: 7-12.

Nuck BA, Fogelson SL, Lucky AW. Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Arch Dermatol 1987; 123: 59-61.

Sato T, Tadokoro T, Sonoda T et al. Minoxidil increases 17 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity of cultured human dermal papilla cells from balding scalp. J Dermatol Sci 1999; 19: 123-5.

Wester RC, Maibach HI, Guy RH et al. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 1984; 82: 515-17.

Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol 1987; 117: 668-9.

Sakita S, Kagoura M, Toyoda M et al. The induction by topical minoxidil of increased fenestration in the perifollicular capillary wall. Br J Dermatol 1999; 140: 294-6.

Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.

Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-17.

Lachgar S, Charveron M, Gall Y et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-11.

Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41: 717-21.

Olsen EA, Dunlap FE, Funicella T et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377-85.

En överväldigande majoritet av klinikerna rekommenderar/nästintill kräver intag av finasterid. Anledningen är inte speciellt konstig. I deras del av universum är bieffekter sällsynta och bromsning av håravfall otvivelaktigt, en s.k. no-brainer.

I många andras delar av universum förefaller substansen kunna medföra mer tråkigheter än acceptabelt. Vari ligger sanningen? Det bestämmer du! Om finas är oaktuellt för dig, end of story, så ska det i sig egentligen inte påverka val av kirurg, eller hur?

Dilemmat här är att man som klinik kanske väljer en betydligt mer försiktig approach när man designar ingreppet om man vet att du inte kommer bromsa med finas..så blir du nekad ingrepp så blir du nekad ingrepp.

Minfoam är en klen tröst för en utsatt hjässa.